264916-06-5

Basic information

• Product Name: TERT-BUTYL 5-AMINOISOINDOLINE-2-CARBOXYLATE
• Synonyms: TERT-BUTYL 5-AMINOISOINDOLINE-2-CARBOXYLATE;5-Amino-1,3-dihydro-2H-isoindole-2-carboxylic acid tert-butyl ester;5-Amino-1,3-dihydroisoindole-2-carboxylic acid tert-butyl ester;5-Amino-2-(tert-butoxycarbonyl)isoindoline;5-Aminoisoindoline-2-carboxylic acid tert-butyl ester;tert-butyl 5-aMinoisoin;tert-butyl 5-aMino-2,3-dihydro-1H-isoindole-2-carboxylate
• CAS NO: 264916-06-5
• Molecular Formula: C₁₃H₁₈N₂O₂
• Molecular Weight: 234.29
• Mol File: 264916-06-5.mol

Chemical Properties

• Boiling Point: 376.304 °C at 760 mmHg
• Flash Point: 181.382 °C
• Appearance: /
• Density: 1.177
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.582
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 4.76±0.20(Predicted)
• CAS DataBase Reference: TERT-BUTYL 5-AMINOISOINDOLINE-2-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL 5-AMINOISOINDOLINE-2-CARBOXYLATE(264916-06-5)
• EPA Substance Registry System: TERT-BUTYL 5-AMINOISOINDOLINE-2-CARBOXYLATE(264916-06-5)

Safety Data

• Hazardous Substances Data: 264916-06-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
TERT-BUTYL 5-AMINOISOINDOLINE-2-CARBOXYLATE is used as a key intermediate in the synthesis of various pharmaceuticals for its potential to contribute to the development of new drugs.
Used in Anti-Tumor Applications:
In the field of oncology, TERT-BUTYL 5-AMINOISOINDOLINE-2-CARBOXYLATE is utilized as a potential anti-tumor agent, being studied for its capacity to impact tumor growth and progression.
Used in Treatment of Lysosomal Storage Disorders:
As a pharmacological chaperone, TERT-BUTYL 5-AMINOISOINDOLINE-2-CARBOXYLATE is applied in the treatment of lysosomal storage disorders, where it may aid in the correction of enzyme deficiencies or dysfunctions.
Used in Synthesis of Heterocyclic Compounds:
In the realm of organic chemistry, TERT-BUTYL 5-AMINOISOINDOLINE-2-CARBOXYLATE is employed as a building block in the synthesis of novel heterocyclic compounds, which may possess unique biological activities and therapeutic potentials.
Used in Medicinal Chemistry:
TERT-BUTYL 5-AMINOISOINDOLINE-2-CARBOXYLATE is leveraged in medicinal chemistry for its potential to enhance the discovery and design of new therapeutic agents, particularly those targeting specific biological pathways or conditions.

InChI:InChI=1/C13H18N2O2/c1-13(2,3)17-12(16)15-7-9-4-5-11(14)6-10(9)8-15/h4-6H,7-8,14H2,1-3H3

Upstream product

• 1059172-96-1 2,2,2-trifluoro-1-(5-nitroisoindolin-2-yl)ethan-1-one 
• 832-51-9 1-(1,3-dihydro-2H-isoindol-2-yl)-2,2,2-trifluoroethanone 
• 496-12-8 isoindoline 
• 46053-72-9 5-nitroisoindoline 
• 24424-99-5 di-tert-butyl dicarbonate 
• 400727-63-1 tert-butyl 5-nitroisoindoline-2-carboxylate 

Downstream Products

• 945488-70-0 N-[4-(N-Boc-isoindolin-5-yl)amino-4-oxobutyryl]-D,L-β-(p-methoxyphenyl)-β-alanine 
• 945488-73-3 N-[4-(N-Boc-isoindolin-5-yl)amino-4-oxobutyryl]-D,L-β-(p-isopropoxyphenyl)-β-alanine 
• 945488-71-1 N-[4-(N-Boc-isoindolin-5-yl)amino-4-oxobutyryl]-D,L-β-(p-ethoxyphenyl)-β-alanine 
• 945488-77-7 N-[4-(N-Boc-isoindolin-5-yl)amino-4-oxobutyryl]-D,L-β-(3,4-dimethoxyphenyl)-β-alanine 
• 945488-72-2 N-[4-(N-Boc-isoindolin-5-yl)amino-4-oxobutyryl]-D,L-β-(p-propoxyphenyl)-β-alanine 
• 945488-75-5 N-[4-(N-Boc-isoindolin-5-yl)amino-4-oxobutyryl]-D,L-β-(p-isobutyloxyphenyl)-β-alanine 
• 945488-74-4 N-[4-(N-Boc-isoindolin-5-yl)amino-4-oxobutyryl]-D,L-β-(p-butoxyphenyl)-β-alanine 
• 945488-76-6 N-[4-(N-Boc-isoindolin-5-yl)amino-4-oxobutyryl]-D,L-β-(p-isopentyloxyphenyl)-β-alanine 
• 807627-84-5 N-[4-(N-Boc-isoindolin-5-yl)amino-4-oxobutyryl]-β-phenyl-β-alanine methyl ester 
• 807627-86-7 N-[4-(N-Boc-isoindolin-5-yl)amino-4-oxobutyryl]-β-phenyl-β-alanine 
• 264916-07-6 2-tert-butoxycarbonyl-5-(2-nitrophenylamino)isoindoline 
• 1264924-32-4 1,1-dimethylethyl 1,3-dihydro-5-[[5-methoxy-6-(4-methylphenyl)-4-pyrimidinyl]amino]-2H-isoindole-2-carboxylate 
• 1264924-35-7 4-[(2,3-dihydro-1H-isoindol-5-yl)amino]-6-(4-methylphenyl)-5-pyrimidinol 

Relevant articles and documents

THIENODIAZEPINE DERIVATIVES AND APPLICATION THEREOF

The present invention relates to a class of thienodiazepine derivatives and an application thereof in the preparation of a drug for the treatment of diseases associated with bromodomain and extra-terminal (BET) Bromodomain inhibitors. Specifically, the present invention relates to compounds represented by formulas (I) and (II), as well as pharmaceutically acceptable salts thereof.

HETEROARYL COMPOUNDS AND USES THEREOF

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same. It has now been found that compounds of this invention, and pharmaceutically acceptable compositions thereof, are effective as inhibitors of one or more protein kinases. Such compounds have general formula I or a pharmaceutically acceptable salt thereof, wherein Ring A, Ring B, W, Ry, R3 and R4 are as defined herein.

PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE

Pyridone and aza-pyridone compounds of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS

The present invention relates to novel heterocyclic compounds of Formulae (I): (Chemical formula should be inserted here as it appears on abstract in paper form) Formula (I) as disclosed herein, or a pharmaceutically acceptable salt, solvate, ester, prodrug or stereoisomer thereof. Also disclosed are pharmaceutical compositions comprising said compounds, and methods for using said compounds for treating or preventing a thromboembolic disorder.

PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES

This application relates to compounds of the general Formula I and salts thereof, wherein X, R1A, R1B, R2, R3, R4, and R5 are as defined herein. The application also relates to compositions and methods of treatment of hyperproliferative diseases or disorders.

4-(Isoindolin-5-yl)amino-4-oxobutyryl-β-alkoxyphenyl-β-alanines, new RGDF mimetics. Synthesis, affinity to fibrinogen receptors, antiaggregatory properties, and their correlation with the hydrophobicity

A new series of RGDF mimetics, derivatives of 4-(isoindolin-5-yl)amino-4- oxobutanoic acid, was synthesized. The compounds obtained inhibit efficiently the thrombocytes aggregation in experiments in vitro; their biological targets are fibrinogen receptors

Novel fibrinogen receptor antagonists. RGDF mimetics, derivatives of 4-(isoindoline-5-yl)amino-4-oxobutyric acid

The novel RGDF mimetics 9a and 9b were synthesized with the use of 4-(isoindoline-5-yl)amino-4-oxobutyric acid as a surrogate of Arg-Gly motif. The synthesized compounds have demonstrated a high potency to inhibit platelet aggregation in vitro and to bloc

1,5-benzodiazepine compounds, their production and use

A compound represented by the formula (I) [wherein ring B represents a cyclic hydrocarbon group which may have substituent(s); Z represents hydrogen atom or a cyclic group which may have substituent(s); R1 represents hydrogen atom, a hydrocarbon group which may have substituent(s), a heterocyclic group which may have substituent(s) or an acyl group; R2 represents amino group which may have substituent(s); D represents a bond or a divalent group; E represents a bond, —CO—, —CON(Ra)—, —COO—, —N(Ra)CON(Rb)—, —N(Ra)COO—, —N(Ra)SO2—, —N(Ra)—, —O—, —S—, —SO— or —SO2— (Ra and Rb each independently represents hydrogen atom or a hydrocarbon group which may have substituent(s)); G represents a bond or a divalent group; L represents a bond or a divalent group; A represents hydrogen atom or a substituent; X and Y each represents hydrogen atom or an independent substituent; and . . . represents that R2 and an atom on ring B may form a ring] or a salt thereof, and a process for producing the same.